Abstract
DNMT3B is an important enzyme to modulate the methylation status in mammalian cells. The aim of this study is to investigate the correlation of the DNMT3B G39179T polymorphism with the susceptibilities of colorectal adenomatous polyps and adenocarcinoma. This case-control study included 146 colorectal adenomatous polyps, 170 colorectal adenocarcinoma patients, and 157 normal controls. DNMT3B polymorphism was analyzed by polymerase chain reaction-restriction fragment length polymorphism analysis. Family history of colorectal cancer significantly increases the risk of developing colorectal adenomatous polyps and adenocarcinoma. The genotype frequency of DNMT3B polymorphism (T/T and G/T + G/G) in adenocarcinoma patients was significantly different from that in controls (P value = 0.01). Compared with DNMT3B T/T genotype, the G allelotype (G/T + G/G genotype) had lower risk to develop colorectal adenocarcinoma (OR = 0.50, 95% CI = 0.29–0.87); while there was no significant difference between the colorectal adenomatous polyps patients and controls (OR = 0.63, 95% CI = 0.37–1.09), although descending tendency could be found in this polyps group. In the stratification analysis, a significant association was confined to subgroups of age < 55 (OR = 0.31, 95% CI = 0.12–0.84) and males (OR = 0.35, 95% CI = 0.17–0.71). Meanwhile, combined G/T + G/G genotypes were found to have a lower risk in non-drinkers to develop both colorectal adenomatous polyps and adenocarcinoma (OR = 0.54, 95% CI = 0.31–0.96 and OR = 0.48, 95% CI = 0.27–0.84, respectively). This study also showed a distinct difference in the distribution of DNMT3B G39179T SNP in different ethnics. DNMT3B G39179T SNP may be a potential genetic susceptibility factor for adenocarcinoma of the colon, especially in younger Chinese Han non-drinker men.
Similar content being viewed by others
References
Lee JJ, Chu E (2007) Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Clin Colorectal Cancer 7(Suppl 1):S16–S20
Morson BC (1978) Symposium on colorectal cancer. 1. Pathology of colorectal cancer. Can J Surg 21:206–208
Giovannucci E, Rimm EB, Ascherio A et al (1995) Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 87:265–273
Linhart HG, Lin H, Yamada Y et al (2007) Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 21:3110–3122
Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167
Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168–174
Bestor T, Laudano A, Mattaliano R, Ingram V (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203:971–983
Okano M, Xie S, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19:219–220
Rhee I, Bachman KE, Park BH et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552–556
Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S (2002) Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 21:4183–4195
Bestor TH (1992) Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J 11:2611–2617
Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247–257
Robertson KD, Uzvolgyi E, Liang G et al (1999) The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27:2291–2298
Shen H, Wang L, Spitz MR et al (2002) A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 62:4992–4995
Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C → T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res 6:R390–R394
Hong YS, Lee HJ, You CH et al (2007) DNMT3b 39179GT polymorphism and the risk of adenocarcinoma of the colon in Koreans. Biochem Genet 45:155–163
Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ (2005) Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep 14:569–573
Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q (2008) Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 268:158–165
Fan H, Zhang F, Hu J, Liu D, Zhao Z (2008) Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J Exp Clin Cancer Res 27:24
Goll MG, Bestor TH (2005) Eukaryotic cytosine methyltransferases. Annu Rev Biochem 74:481–514
Schmidt WM, Sedivy R, Forstner B et al (2007) Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol Carcinog 46:766–772
Kim H, Kwon YM, Kim JS et al (2006) Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 107:1042–1049
Chen CL, Yan X, Gao YN, Liao QP (2005) Expression of DNA methyltransferase 1, 3A and 3B mRNA in the epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 40:770–774
Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H (2003) Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol 22:1201–1207
Saito Y, Kanai Y, Nakagawa T et al (2003) Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 105:527–532
Buckland PR (2006) The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 1762:17–28
Lee SJ, Jeon HS, Jang JS et al (2005) DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26:403–409
Fan H, Liu DS, Zhang SH et al (2008) DNMT3B 579 G > T promoter polymorphism and risk of esophagus carcinoma in Chinese. World J Gastroenterol 14:2230–2234
Chang KP, Hao SP, Liu CT et al (2007) Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol 43:345–351
Lee GY, Jang JS, Lee SY et al (2005) XPC polymorphisms and lung cancer risk. Int J Cancer 115:807–813
Neugut AI, Jacobson JS, De Vivo I (1993) Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 2:159–176
Fahy B, Bold RJ (1998) Epidemiology and molecular genetics of colorectal cancer. Surg Oncol 7:115–123
Cappell MS (2008) Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am 37:1–24 v
Ryan BM, Weir DG (2001) Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med 138:164–176
Mizoue T, Inoue M, Wakai K et al (2008) Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol 167:1397–1406
Homann N, Tillonen J, Salaspuro M (2000) Microbially produced acetaldehyde from ethanol may increase the risk of colon cancer via folate deficiency. Int J Cancer 86:169–173
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guo, X., Zhang, L., Wu, M. et al. Association of the DNMT3B polymorphism with colorectal adenomatous polyps and adenocarcinoma. Mol Biol Rep 37, 219–225 (2010). https://doi.org/10.1007/s11033-009-9626-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-009-9626-z